OMass Therapeutics

Many potentially important disease targets are considered ‘undruggable’ because traditional tools can’t capture how they behave in the body.

OMass Therapeutics is changing that. Founded by Professor Dame Carol Robinson, its OdyssION™ platform uses high-resolution native mass spectrometry to study intact protein complexes in their natural environment, revealing how they interact and enabling precision approaches to drug discovery screening. This opens up new possibilities in drug discovery, with the company’s pipeline focused on endocrinology and immunology.